In two double blind placebo controlled clinical trials conducted at the Rutgers University Human Performance Lab SURGEX(TM) significantly outperformed leading competitive products by assisting in reducing the damaging effects of exercise. SURGEX(TM) proved to be a superior product by improving peak power outputs, lowering oxidative stress/inflammatory markers, reducing fatigue (poor energy recovery) and the breakdown of muscle (post exercise wasting), as well as reducing free radical production (oxidative stress). The formula meets NCAA guidelines for use by collegiate athletes and is certified by The Banned Substances Control Group (BSCG) to contain no banned substances.
Statements in this news release regarding future financial and
operating results, future growth in R&D programs, potential applications of
the Company's technology, opportunities for the Company, and any other
statements about the future expectations, beliefs, goals, plans, or
prospects expressed constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words "will," "believes," "plans," "anticipates," "expects,"
"estimates," and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that
could cause actual results or events to differ materially from those
indicated by such forward- looking statements including: limited operating
history, need for future capital, risks inherent in the development and
commercialization of potential products, protection of the Company's
intellectual property, and economic conditions generally. Additional
information on potential factors that could affect results and other risks
|SOURCE Millennium Biotechnologies Inc.|
Copyright©2008 PR Newswire.
All rights reserved